ReviewCurrent neurology and neuroscience reports2015
Nanotheragnostic applications for ischemic and hemorrhagic strokes: improved delivery for a better prognosis.
Review in Current neurology and neuroscience reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Targeted delivery of curcumin based on nanocarriers: potential therapeutic strategies for noninfectious arthritis.Inflammopharmacology · 2026Review
- The Importance of Increased Serum GFAP and UCH-L1 Levels in Distinguishing Large Vessel from Small Vessel Occlusion in Acute Ischemic Stroke.Biomedicines · 2024Article
- Advances of nano drug delivery system for the theranostics of ischemic stroke.Journal of nanobiotechnology · 2022Review
- PLGA-Based Curcumin Delivery System: An Interesting Therapeutic Approach in the Treatment of Alzheimer's Disease.Current neuropharmacology · 2022Review
- Extracellular matrix metalloproteinase inducer in brain ischemia and intracerebral hemorrhage.Frontiers in immunology · 2022Review
- Dodging blood brain barrier with "nano" warriors: Novel strategy against ischemic stroke.Theranostics · 2022Review
- Recent advances in the development of nanomedicines for the treatment of ischemic stroke.Bioactive materials · 2021Review
- Curcumin-loaded nanoparticles: a novel therapeutic strategy in treatment of central nervous system disorders.International journal of nanomedicine · 2019Review
- Advances in Nano Neuroscience: From Nanomaterials to Nanotools.Frontiers in neuroscience · 2018Review
- Recent Advances in the Therapeutic and Diagnostic Use of Liposomes and Carbon Nanomaterials in Ischemic Stroke.Frontiers in neuroscience · 2018Review
- Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is the second leading cause of death worldwide and a major cause of long-term severe disability representing a global health burden and one of the highly researched medical conditions. Nanostructured material synthesis and engineering have been recently developed and have been largely integrated into many fields including medicine. Recent studies have shown that nanoparticles might be a valuable tool in stroke. Different types, shapes, and sizes of nanoparticles have been used for molecular/biomarker profiling and imaging to help in early diagnosis and prevention of stroke and for drug/RNA delivery for improved treatment and neuroprotection. However, these promising applications have limitations, including cytotoxicity, which hindered their adoption into clinical use. Future research is warranted to fully develop and effectively and safely translate nanoparticles for stroke diagnosis and treatment into the clinic. This work will discuss the emerging role of nanotheragnostics in stroke diagnosis and treatment applications.
Indexed as
Identifiers
25394858What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.